While there is currently no cure for geographic atrophy, certain treatments, such as complement inhibitors, can help slow its progression by targeting immune system activity that damages the macula.

FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye, and it marks the first of a three-part series on dry ...

There is currently no cure for geographic atrophy (GA) – in other words, no effective therapy to entirely halt the disease process, restore vision or reverse the damage to the retina. Currently ...

PARSIPPANY, N.J.--(BUSINESS WIRE)-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company’s New Drug ...

SAN FRANCISCO -- A neuroprotective approach to geographic atrophy (GA) had a time-dependent effect on lesion growth and a significant impact on visual acuity, an early study showed. Overall, the ...

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...

Early screening for geographic atrophy may help slow progression to foveal involvement. Collaborating with optometrists on geographic atrophy care is beneficial for patients. Healio spoke with Yasha S ...

An Iveric Bio drug at the heart of a $5.9 billion Astellas Pharma acquisition has received FDA approval, making it just the second approved therapy for a common vision loss-disorder that afflicts an ...

WALTHAM, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug ...